Strides Pharma Science Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

Price Movement and Market Context

On 19 Jan 2026, Strides Pharma Science Ltd closed at ₹896.05, down from the previous close of ₹939.65, marking a 4.64% decrease. The stock traded within a range of ₹888.80 to ₹944.60 during the day, well below its 52-week high of ₹1,024.90 but comfortably above the 52-week low of ₹530.70. This volatility reflects a short-term correction amid broader market fluctuations.

Comparatively, the Sensex showed a negligible weekly return of -0.01%, while Strides Pharma’s weekly return was a sharper -4.98%. However, over the one-month horizon, the stock outperformed the benchmark with a 2.62% gain against Sensex’s -1.31%. Year-to-date, Strides Pharma is marginally down by 0.70%, outperforming the Sensex’s -1.94% decline. The stock’s one-year return of 43.41% significantly surpasses the Sensex’s 8.47%, underscoring its strong medium-term growth trajectory.

Technical Trend Analysis

Recent technical assessments indicate a shift in Strides Pharma’s trend from bullish to mildly bullish. This subtle change suggests that while the stock retains upward momentum, the strength of the trend has moderated, warranting closer scrutiny by investors.

The Moving Averages on the daily chart remain mildly bullish, signalling that short-term price averages continue to support upward movement. However, weekly and monthly indicators present a more mixed outlook.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator, a key momentum gauge, is mildly bearish on both weekly and monthly timeframes. This suggests that the momentum behind recent price gains is weakening, potentially foreshadowing a consolidation phase or minor correction. The MACD’s bearish tone contrasts with the daily moving averages, highlighting the divergence between short-term and longer-term momentum.

The Know Sure Thing (KST) indicator offers a split view: bullish on the weekly scale but mildly bearish monthly. This divergence indicates that while short-term momentum remains positive, longer-term momentum is under pressure, reflecting uncertainty in the stock’s directional strength.

Relative Strength Index and Bollinger Bands

The Relative Strength Index (RSI) shows no clear signal on weekly and monthly charts, implying that the stock is neither overbought nor oversold in these periods. This neutral RSI reading suggests a balanced market sentiment without extreme buying or selling pressure.

Bollinger Bands, which measure volatility and price levels relative to recent averages, are mildly bullish on both weekly and monthly timeframes. This indicates that price movements are trending towards the upper band, signalling potential upward momentum but with caution due to the mild nature of the signal.

Volume and Trend Confirmation

On-Balance Volume (OBV) is mildly bullish weekly but mildly bearish monthly, reflecting a divergence between short-term buying interest and longer-term volume trends. This mixed volume pattern suggests that while recent trading activity supports price gains, the broader volume trend may be weakening.

Dow Theory assessments show no clear trend on the weekly scale and a mildly bearish stance monthly, reinforcing the cautious tone from other monthly indicators.

Mojo Score and Rating Update

Strides Pharma Science Ltd currently holds a Mojo Score of 50.0, reflecting a neutral stance in terms of fundamental and technical factors. The Mojo Grade was upgraded from Sell to Hold on 29 Sep 2025, signalling improved investor confidence but still cautioning against aggressive buying. The Market Cap Grade stands at 3, indicating a mid-tier market capitalisation relative to peers in the Pharmaceuticals & Biotechnology sector.

This rating upgrade aligns with the mixed technical signals, suggesting that while the stock has stabilised from previous bearish pressures, it has yet to demonstrate a strong bullish breakout.

Long-Term Performance and Sector Comparison

Over the past five years, Strides Pharma has delivered a remarkable 105.36% return, outperforming the Sensex’s 70.43% gain. The three-year return is even more impressive at 457.98%, dwarfing the Sensex’s 39.07%. However, the ten-year return of 75.40% trails the Sensex’s 241.73%, indicating that the stock’s recent growth has been more pronounced than its long-term average.

Within the Pharmaceuticals & Biotechnology sector, Strides Pharma’s performance is notable for its volatility and growth spurts, reflecting the sector’s sensitivity to regulatory developments, innovation cycles, and market sentiment.

Investor Implications and Outlook

Investors should weigh the mildly bullish daily moving averages and Bollinger Bands against the mildly bearish MACD and KST monthly signals. The absence of strong RSI signals suggests a wait-and-watch approach may be prudent until clearer momentum emerges.

Given the stock’s recent downgrade in daily price and mixed volume trends, cautious investors might consider partial profit-taking or hedging strategies, while more risk-tolerant participants could view current levels as an opportunity to accumulate on dips, anticipating a potential rebound supported by the weekly bullish KST and Bollinger Bands.

Summary

Strides Pharma Science Ltd’s technical landscape is characterised by a delicate balance between bullish and bearish signals. While daily indicators suggest mild bullishness, weekly and monthly momentum indicators caution investors about potential volatility and trend uncertainty. The stock’s strong medium-term returns and recent rating upgrade to Hold provide a foundation for optimism, but the current price correction and mixed volume trends advise prudence.

Investors should monitor key technical levels and volume patterns closely, considering both sector dynamics and broader market conditions before making significant portfolio adjustments.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →